Harold Bernstein Offloads 4,432 Shares of Maze Therapeutics Stock

Maze Therapeutics, Inc. (NASDAQ: MAZE) has witnessed significant stock transactions involving its Chief Medical Officer, Harold Bernstein. On January 2, 2024, Bernstein sold 4,432 shares of the company’s stock for an average price of $40.43, totaling $179,185.76. This transaction was reported in a legal filing with the Securities and Exchange Commission, accessible on the SEC’s website.

In subsequent trades, Bernstein further reduced his holdings. On January 5, he sold 412 shares at an average price of $40.00, amounting to $16,480.00. Earlier, on December 29, 2023, he sold 45,000 shares at an average price of $40.56, generating a total value of $1,825,200.00.

Maze Therapeutics Stock Performance

Following these trades, shares of Maze Therapeutics experienced a decline. On January 2, 2024, the stock fell by $0.26 during mid-day trading, reaching $38.37. A total of 241,160 shares were traded, which is below the average volume of 330,787 shares. The company currently has a market capitalization of $1.85 billion and a price-to-earnings ratio of -1.84. Over the past fifty days, the stock has maintained a moving average price of $37.15, while its 200-day moving average stands at $25.26. The stock’s performance over the last year has ranged from a low of $6.71 to a high of $43.29.

Institutional Investment Trends

Maze Therapeutics has seen varied activity from institutional investors recently. JPMorgan Chase & Co. increased its stake in the company by 80.7% during the third quarter, now holding 7,890 shares valued at $205,000 after acquiring an additional 3,524 shares. Other significant movements include Woodline Partners LP, which boosted its holdings by 10.0%, now owning 1,035,229 shares worth $26,843,000, and Susquehanna International Group LLP, which increased its stake by 53.0%.

Additionally, XTX Topco Ltd. initiated a new position in Maze Therapeutics valued at $697,000, while Parkman Healthcare Partners LLC also entered with a new stake of $5,186,000 during the same quarter.

Analyst Ratings and Market Outlook

Recent evaluations from several research firms indicate a positive outlook for Maze Therapeutics. Wall Street Zen upgraded the stock from a “sell” to a “hold” rating on December 13, 2023. Wells Fargo & Company initiated coverage with an “overweight” rating and a target price of $55.00 on December 4. Raymond James Financial also began coverage, issuing an “outperform” rating with a target price of $48.00.

Moreover, JPMorgan Chase & Co. raised its target price from $27.00 to $37.00, maintaining an “overweight” rating. Wedbush also adjusted its price target from $35.00 to $36.00, giving the stock an “outperform” rating.

With these insights, analysts have rated Maze Therapeutics as a “Buy” with a consensus price target of $43.38, according to data from MarketBeat.

Maze Therapeutics, Inc. focuses on discovering and developing novel therapeutics by leveraging insights from human genetics and genomics. The company utilizes advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to enhance drug discovery and expedite the development of treatments for serious diseases. Since its founding, Maze has developed a diverse pipeline of programs across various therapeutic areas, including metabolic and immunological conditions.